Business Wire

BIT.BIO

28.10.2021 10:25:07 CEST | Business Wire | Press release

Share
bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate

Today bit.bio welcomes three new members to its board of directors, who bring their respective experience of turning world class science into new industries and company growth. The new directors will provide important guidance as bit.bio scales their proprietary synthetic biology cell programming technology platform, creating products and solutions based on human cells that can transform healthcare from basic research and drug discovery to next generation cell based therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005473/en/

Hermann Hauser will be the chair of the board. He brings valuable experience in creating entire new industries and markets through groundbreaking technologies with his experience as co-founder of Arm Ltd. holdings, a world leading UK computer chip company. As an early investor of Solexa (now Illumina), Dr. Hauser laid the foundation for the ongoing synthetic biology revolution with technologies to read the human genome. He is also a key member of the Cambridge science and technology community, as well as a trusted innovation advisor of the UK government. Dr. Hauser is a fellow of the Royal Society, KBE and co-founder of the venture capital firm Amadeus Capital Partners.

Hermann Hauser said:

“I believe bit.bio is well positioned to become one of the defining companies in the synthetic biology field, and I am very excited to take the position of chair of the board. I see world changing potential in their technology and look forward to bringing my experience and expertise to the leadership team. I want to see bit.bio grow into an iconic Cambridge company, creating jobs and new industries, and most importantly, bringing the next generation of medicines to patients.”

Sir Gregory Winter is a Nobel prize winning scientist who invented technologies for making therapeutic monoclonal antibodies, and was directly involved in their industrial development, notably through the start up company Cambridge Antibody Technology Ltd. His inventions underpin many of the therapeutic antibodies in development and on the market, including blockbuster drugs such as Humira, Herceptin, Avastin and Keytruda. More recently, through Bicycle Therapeutics, he has been helping to develop another invention - the use of bicyclic peptides as a platform for novel therapeutics.

Sir Gregory Winter said:

“I think we are still in the foothills when it comes to the use of human cells for therapeutic applications, and I am excited to join bit.bio on their journey to the peaks. With access to potentially unlimited numbers of human cells at defined states of differentiation, we could do so much more for patients - whether researching difficult to treat, complex diseases, screening potential drugs on human cells, or developing precision cell therapies at an affordable cost. And the opti-ox technology seems to offer a realistic path to scale those peaks.”

Alan S. Roemer will bring his entrepreneurial expertise from the biotechnology sector to bit.bio. As a life sciences executive and board director, he will offer meaningful capital markets and operational business building experience to ensure that bit.bio is well-financed and well-positioned to scale. Mr. Roemer has launched three multi-billion dollar biotechnology companies, raised over $1.75 billion in private and public capital, and consummated five IPOs. He was a founding leadership team member of Pharmasset (acquired by Gilead Sciences for $11 billion ) and Roivant Sciences, a company developing innovative medicines through a novel form of industrial organisation in R&D. His experience at Roivant is particularly relevant to bit.bio’s strategy to build its cell coding technology opti-ox into multiple verticals where human cells are applied to research, drug discovery and cell therapies. In addition to serving as a member of the board, Mr. Roemer will chair the audit and compensation committees.

Alan Roemer said:

"bit.bio is at that exciting stage of growth and evolution that I have been through several times before. It fuels my entrepreneurial spirit with the ‘fun factor’ of company expansion and cultural impact. I am excited to help the leadership team ‘see around corners’ using my experience from my other high-growth companies. Most importantly, I want to provide meaningful guidance to finance and scale the business, exploit the full potential of bit.bio’s core technology and have the potential to positively impact patients' lives.”

Mark Kotter, founder and CEO of bit.bio said:

“I’m humbled to be bringing together three world leaders in science, entrepreneurship and industry making for the board of bit.bio. The expertise and experience our new board will bring to the company will give our technology the best chance to transform healthcare for every patient, everywhere.”

- ENDS -

About bit.bio
Accelerated biomedical research, new generations of cures, increased global sustainability. These are in reach when biology transitions to engineering.

At bit.bio, we work relentlessly to achieve this goal. We combine the concepts of coding and biology to provide human cells for research, drug discovery, and a new generation of medicines.

For more information visit bit.bio

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release

On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con

ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release

ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer

Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release

Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population

Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 14:30:00 CET | Press release

Klarna is Adyen’s first non-card, local payment method for agentic commerce Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specificat

SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release

India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye